Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.

Cancer letters - 28 Jun 2009

Duarte Mariana Lemos, de Moraes Emanuela, Pontes Elizangela, Schluckebier Luciene, de Moraes Joyce Luana, Hainaut Pierre, Ferreira Carlos Gil

Abstract excerpt

Non-small cell lung Cancer (NSCLC) is extremely resistant to chemotherapeutic agents, such as cisplatin. High expression of the inflammatory enzyme cyclooxygenase-2 (COX-2) has been shown to inhibit chemotherapy-induced apoptosis, but little is known about COX-2 regulation upon drug treatment. Recent data indicate the tumor suppressor protein p53 as an important regulator of COX-2. Therefore, TP53 status could...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cisplatin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclooxygenase 2

Share to Dinoprostone

Share to Enzyme Induction

Share to Paclitaxel

Share to RNA Interference

Share to RNA, Small Interfering

Source

Identifiers

PMID: 19217709
DOI: 10.1016/j.canlet.2009.01.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.PMID 19217709Read ↗

p53-independent apoptosis induced by paclitaxel through an indirect mechanismSemantic proximity Read ↗

p53 gene expression and 2-methoxyestradiol treatment differentially induce nuclear factor kappa B activation in human lung cancer cells with different p53 phenotypes.Semantic proximity Read ↗

Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.Semantic proximity Read ↗

Inhibition of Cyclooxygenase-2 Gene Expression by p53Semantic proximity Read ↗

The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.Semantic proximity Read ↗

Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cellsSemantic proximity Read ↗

Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependentSemantic proximity Read ↗

The relationship between cisplatin - induced apoptosis and p53 , bcl - 2 and bax expression in human lung cancer cellsSemantic proximity Read ↗

Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry.Semantic proximity Read ↗

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.Semantic proximity Read ↗

Knockdown of CITED2 using short‐hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53‐dependent apoptosisSemantic proximity Read ↗

Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 statusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.